COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Safety Study of the Angel™ Catheter in Subjects With Risk of Pulmonary Embolism

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01403090
Recruitment Status : Completed
First Posted : July 27, 2011
Results First Posted : May 20, 2013
Last Update Posted : May 20, 2013
Information provided by (Responsible Party):
BiO2 Medical

Brief Summary:
The Angel™ Catheter combines the functions of a vena cava filter and a multi-lumen central line catheter. The device is designed to be placed in the inferior vena cava via the femoral vein for the prevention of Pulmonary Embolism (PE) and for access to the central venous system. The primary endpoint is freedom from serious adverse events (SAE), defined as death, symptomatic pulmonary embolism or major bleeding .

Condition or disease Intervention/treatment Phase
Pulmonary Embolism Deep Vein Thrombosis Venous Thromboembolism Device: Angel Catheter Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 8 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Single Treatment, Open Label, Multicenter, Safety Study of the Angel™ Catheter in Hospitalized Human Subjects With a Temporary Risk of Pulmonary Embolism
Study Start Date : December 2011
Actual Primary Completion Date : March 2012
Actual Study Completion Date : March 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Angel Catheter Device: Angel Catheter
The Angel Catheter will be inserted in the femoral vein following standard central line placement techniques. Once the catheter is on the Inferior Vena Cava, the filter will be deployed following the manufacturer instructions and secured to the skin.

Primary Outcome Measures :
  1. Safety [ Time Frame: 30 days ]
    Device safety was evaluated on the basis of identification and summarization of the incidence rates of complications and adverse effects.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subject is 18 years and older
  2. Be admitted to the hospital

    One of the following two criteria:

  3. Patients with proven deep vein thrombosis (DVT) or pulmonary embolism ( PE), at high risk for pulmonary embolism and under consideration for insertion of a retrievable inferior vena cava (IVC) filter with at least one of the following criteria:

    • Contraindications for anticoagulation
    • Recurrent PE despite adequate anticoagulation
    • Emergency treatment following massive pulmonary embolism
  4. Patients at high risk for developing PE who require but have a temporary or absolute contraindication for prophylaxis with anticoagulation, including:

    • Patients with multiple trauma and active or recent bleeding with contraindications to anticoagulation or that require a temporary stop of anticoagulation
    • severe head injury with coma
    • severe hemorrhagic stroke with coma
    • head injury with a long bone fracture
    • spinal cord injury with paraplegia or quadriplegia
    • multiple (≥2) long bone fractures with pelvic fracture
    • multiple (≥4) long bone fractures
    • Critically ill patients in the Medical or Surgical Intensive Care Unit with high risk of PE that require but are contraindicated for anticoagulation prophylaxis and will benefit from a temporary filter and a central venous access catheter
    • Patients who had recently undergone or are about to undergo a surgical procedure that requires temporary interruption of anticoagulation for Venous Thromboembolism (VTE) and will benefit from a temporary vena cava filter and central

Exclusion Criteria:

  1. Patient is less than 18 years
  2. Patient is pregnant or has a positive serum human chorionic gonadotropin (HCG) pregnancy test at baseline visit
  3. Patient or next legal representative cannot give informed consent
  4. Patients with anticipated survival < 2 days (catastrophic illness)
  5. Body mass index greater than 35
  6. Patient has a pre-existing filter
  7. Participation in another simultaneous interventional medical investigation or interventional trial.
  8. Patient has indications for a permanent filter at the time of the initial evaluation
  9. Patient has an uncontrollable coagulopathy with active bleeding.
  10. Patient with proven endocarditis or bacteremia
  11. Patient has hypersensitivity to any of the components of the Angel™ Catheter, specifically Nitinol
  12. Known acute or chronic thrombotic occlusion of both common femoral veins or iliac veins
  13. Patient with functioning pelvic renal allograft on the only side available for device insertion
  14. Patient who will undergo surgical procedure involving the femoral vein or pelvic veins through which the device must be inserted

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01403090

Layout table for location information
Clinica las Americas
Medellin, Antioquia, Colombia
Hospital Pablo Tobon Uribe
Medellin, Antioquia, Colombia
Sponsors and Collaborators
BiO2 Medical
Layout table for investigator information
Principal Investigator: Carlos Cadavid, MD Hospital Pablo Tobon Uribe
Principal Investigator: Bladimir Gil, MD Clinica Las Americas
Layout table for additonal information
Responsible Party: BiO2 Medical Identifier: NCT01403090    
Other Study ID Numbers: CPR-001
First Posted: July 27, 2011    Key Record Dates
Results First Posted: May 20, 2013
Last Update Posted: May 20, 2013
Last Verified: April 2013
Keywords provided by BiO2 Medical:
Pulmonary Embolism
Deep Vein Thrombosis
Venous Thromboembolism
Central Line Catheter
Vena Cava Filters
Additional relevant MeSH terms:
Layout table for MeSH terms
Pulmonary Embolism
Venous Thromboembolism
Venous Thrombosis
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases